Shukra Medtech Q2 FY27 Results: Consolidated Net Profit ₹11.27 Crore on Total Income of ₹44.78 Crore
- Earnings
- Pharmaceuticals and medical technology
Reviewed byRachit TripathiBlacklitt Research
Shukra Medtech reported consolidated total income of ₹44.78 crore and net profit of ₹11.27 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹44.78 crore and net profit of ₹16.01 crore, it said in a filing on 04 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹44.78 crore, up 489.9% YoY and 86.1% QoQ
- Net profit: ₹11.27 crore, up 374.0% YoY and down 13.0% QoQ
- EPS: ₹0.29 basic, against ₹0.05 a year earlier and ₹0.30 in Q1 FY27
- Finance costs: ₹0.33 crore, against ₹0.29 crore a year earlier
Standalone
The company on its own, without its subsidiaries
- Total income: ₹44.78 crore, up 489.9% YoY and 86.1% QoQ
- Net profit: ₹16.01 crore, up 573.3% YoY and 6.5% QoQ
- EPS: ₹0.36 basic, against ₹0.05 a year earlier and ₹0.33 in Q1 FY27
- Medtech segment revenue: ₹12.51 crore for the quarter, none in the prior quarter or year-ago quarter
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 44.78 | 7.59 | +489.9% | 24.06 | +86.1% | |
| Revenue from operations | 44.78 | 7.59 | +489.9% | 24.06 | +86.1% |
| Other income | 0.57 | 1.71 | -66.6% | 0.54 | +6.0% |
| 11.27 | 2.38 | +374.0% | 12.96 | -13.0% | |
| Profit before tax | 17.83 | 0.20 | n/a | 18.17 | -1.9% |
| Finance costs | 0.33 | 0.29 | +16.6% | 0.43 | -22.7% |
| Depreciation | 1.12 | 0.81 | +37.9% | 1.08 | +3.1% |
| Tax expense | 6.55 | -2.18 | n/a | 5.21 | +25.7% |
| Net profit margin | 25.17% | 31.33% | -6.16 pp | 53.85% | -28.68 pp |
| EPS, basic (₹) | 0.29 | 0.05 | +480.0% | 0.30 | -3.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated total income grew far faster than the rise in profit. Total income of ₹44.78 crore is up 489.9% from ₹7.59 crore a year before, while net profit of ₹11.27 crore is up 374.0% from ₹2.38 crore. Profit before tax was ₹17.83 crore against ₹0.20 crore a year before, and tax expense of ₹6.55 crore is 36.7% of profit before tax, compared with a tax credit of ₹2.18 crore in the year-ago quarter.
Against the previous quarter, income rose while profit fell. Total income rose 86.1% to ₹44.78 crore from ₹24.06 crore, but net profit fell 13.0% to ₹11.27 crore from ₹12.96 crore, and profit before tax fell 1.9%. Tax expense rose 25.7% to ₹6.55 crore from ₹5.21 crore.
Other income is a small part of this quarter's result. At ₹0.57 crore it is 1.3% of total income and 3.2% of profit before tax, and it is down 66.6% from ₹1.71 crore a year earlier. Finance costs of ₹0.33 crore are 0.7% of total income, up 16.6% from ₹0.29 crore a year before.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 44.78 | 7.59 | +489.9% | 24.06 | +86.1% | |
| Revenue from operations | 44.20 | 5.88 | +652.1% | 23.52 | +87.9% |
| Other income | 0.57 | 1.71 | -66.6% | 0.54 | +6.0% |
| 16.01 | 2.38 | +573.3% | 15.03 | +6.5% | |
| Profit before tax | 21.13 | 0.20 | n/a | 20.24 | +4.4% |
| Finance costs | 0.33 | 0.29 | +16.6% | 0.43 | -22.7% |
| Depreciation | 1.12 | 0.81 | +39.0% | 1.07 | +4.7% |
| Tax expense | 5.12 | -2.18 | n/a | 5.21 | -1.9% |
| Net profit margin | 35.76% | 31.33% | +4.43 pp | 62.46% | -26.70 pp |
| EPS, basic (₹) | 0.36 | 0.05 | +620.0% | 0.33 | +9.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit grew faster than consolidated profit. Net profit of ₹16.01 crore is up 573.3% from ₹2.38 crore a year before and up 6.5% from ₹15.03 crore in the previous quarter, while total income rose 86.1% QoQ. Consolidated net profit of ₹11.27 crore is ₹4.74 crore lower than standalone.
Standalone revenue from operations is ₹44.20 crore, against consolidated revenue from operations of ₹44.78 crore. Standalone profit before tax of ₹21.13 crore is up from ₹20.24 crore in the previous quarter, and tax expense of ₹5.12 crore is 24.2% of it.
The standalone statement shows Medtech segment revenue of ₹12.51 crore for the quarter ended 30 Sep 2026. The company says it operates two segments, Shukra Pharmaceutical and Shukra MedTech, and the MedTech segment name has applied from 1 Oct 2025. The statement shows no Medtech revenue in the previous quarter or the year-ago quarter.
Inference
The filing says the company converted convertible warrants issued on a preferential basis into equity shares in the half year, taking equity share capital to ₹44.08 crore at 30 Sep 2026, with a face value of ₹1 per share. It records 0 investor complaints in the half year.
The name changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited with effect from 12 Oct 2026. The statutory auditors issued limited review reports with an unmodified conclusion on both statements; the consolidated report notes eight subsidiaries with total assets of ₹37.20 lakh, which it says are not material to the group.
Neither a dividend nor the reason for the revenue rise or the quarter-on-quarter fall in consolidated profit is stated in the text read.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
